Not Signed In -
Ethinyl Estradiol and Norethindrone (Oral Contraceptive) |
Brevicon; Estrostep 21; Estrostep Fe; Gencept 0.5/35; Gencept 1/35; Gencept 10/11; Genora 0.5/35; Genora 1/35; Jenest-28; Loestrin 21 1.5/30; Loestrin 21 1/20; Loestrin Fe 1.5/30; Loestrin Fe 1/20; Microgestin Fe 1.5/30; Microgestin Fe 1/20; Modicon; N. E. E.; Necon 0.5/35; Necon 1/35; Necon 10/11; Necon 7/7/7; Nelova 0.5/35 E; Nelova 1/35 E; Nelova 10/11; Norcept-E 1/35; Norethin 1/35 E; Norinyl 1+35; Nortrel 0.5/35; Nortrel 1/35; Nortrel 7/7/7; Ortho-Novum 1/35; Ortho-Novum 10/11; Ortho-Novum 7/7/7; Ovcon-35; Ovcon-50; Tri-Norinyl |
Pictures
femhrt3 gif
NA EE 1 10 tablet Figure 1 Mean Steady State Day 87 Plasma Norethindrone and Ethinyl Estradiol Concentrations Following Continuous Oral Administration of 1 mg NA 10 mcg EE Tablets
loestrin 24fe4 gif
Table 1 Summary of Norethindrone NE and Ethinyl Estradiol EE Pharmacokinetics Following Single and Multiple Dose Oral Administration of Loestrin 24 Fe Tablets to Healthy
loestrin 24fe3 gif
Figure 2 Mean Plasma Ethinyl Estradiol Concentration Time Profiles Following Single and Multiple Dose Oral Administration of Loestrin 24 Fe Tablets to Healthy Female Volunteers
loestrin 24fe5 gif
the age of 40 Figure 3 among women who use oral contraceptives FIGURE 3 CIRCULATORY DISEASE MORTALITY RATES FOR 100 000 WOMEN YEARS BY AGE SMOKING STATUS AND ORAL CONTRACEPTIVE USE Layde PM Beral V Lancet 1981 1 541 546 Oral contraceptives may compound the effects of well known risk factors such as hypertension diabetes hyperlipidemias age and obesity In
dissolution detail1B x1982 jpg
oral contraceptive containing ethinyl estradiol and norethindrone in one fully automated HPLC run using both fluorescence and UV detection Fluorescence detection for ethinyl estradiol UV detection for norethindrone
dissolution detail1A x1982 jpg
for the analysis of the components of a common oral contraceptive containing ethinyl estradiol and norethindrone in one fully automated HPLC run using both fluorescence and UV detection Fluorescence detection for ethinyl estradiol UV detection for norethindrone
estrostep wcp fig3 gif
Figure 3 Oral contraceptives may compound the effects of well known risk factors such as hypertension diabetes hyperlipidemias age and obesity In particular some progestogens are known to
images26 jpeg
Oral Contraceptive Based on AUC and half life multiple dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2 5 mg of
28 day ovcon 50 01 jpg
regimen for oral contraception derived from 21 tablets composed of norethindrone and ethinyl estradiol to be followed by 7 green tablets of inert ingredients The structural formulas are The active Ovcon 35 tablets contain 0 4 mg norethindrone and 0 035 mg ethinyl estradiol The active Ovcon 50 tablets contain 1 mg norethindrone and 0 05 mg ethinyl estradiol The green
28 day ovcon 50 17 jpg
PATIENT PACKAGE INSERT BRIEF SUMMARY 28 DAY Norethindrone and Ethinyl Estradiol Tablets USP This product like all oral contraceptives is intended to prevent pregnancy It does not protect against HIV infection AIDS and other
28 day ovcon 50 09 jpg
PATIENT PACKAGE INSERT BRIEF SUMMARY 21 DAY Norethindrone and Ethinyl Estradiol Tablets USP This product like all oral contraceptives is intended to prevent pregnancy It does not protect against HIV infection AIDS and other
email this page
print this page
bookmark this page
feedback on this page
